Every Question.
Answered.

Methylene blue (methylthioninium chloride) is a pharmaceutical-grade compound first synthesized in 1876. It functions as a mitochondrial electron carrier, accepting electrons from NADH and donating them directly to cytochrome c in the electron transport chain. It has 150+ peer-reviewed studies and FDA recognition as a pharmaceutical antidote for methemoglobinemia.

Methylene blue crosses the blood-brain barrier and accumulates preferentially in mitochondria-dense tissues. It acts as an alternative electron carrier at Complex I and IV of the mitochondrial electron transport chain, improving ATP synthesis efficiency and reducing reactive oxygen species (ROS) production. This dual action — more energy, less oxidative damage — is the mechanism behind its longevity and cognitive research.

Yes. Methylene blue readily crosses the blood-brain barrier due to its small molecular weight and lipophilic properties. It preferentially accumulates in mitochondria-rich neural tissue, which is why cognitive and neuroprotective effects are among its most-studied benefits.

Yes, "methylene blue" and "blue methylene" refer to the same compound: methylthioninium chloride. Other names include Basic Blue 9, Tetramethylthionine chloride, and Urolene Blue (pharmaceutical brand).

Pharmaceutical-grade (USP) methylene blue meets strict purity standards (99.9%+ purity, verified heavy metal content, endotoxin testing). Lab-grade methylene blue is intended for laboratory staining — it may contain heavy metals and contaminants that are acceptable in a microscopy stain but unsafe for human consumption. Always use USP pharmaceutical-grade for supplementation.

The evidence-based range is 4–30 mg/day. Methylene blue has a hormetic (inverted-U) dose-response curve: below 4mg is sub-therapeutic; 4–30mg is the benefit window for cognitive and mitochondrial effects; above 30mg benefits plateau and side effects (blue urine, nausea) increase. Most users start at 4mg and titrate up based on response.

Once daily in the morning is the most common protocol. Some users cycle (5 days on, 2 days off) as a precaution, though there is no RCT data specifically supporting or refuting cycling.

Yes. Above 2 mg/kg body weight, methylene blue can cause methemoglobinemia — the opposite of its therapeutic action at low doses. Recreational high-dose use is dangerous. Supplement doses should stay within 4–30 mg/day.

Morning with water is preferred. Methylene blue can mildly increase alertness and energy production — evening use may interfere with sleep in sensitive individuals.

No specific food requirement. Taking with food may reduce nausea in sensitive individuals. Avoid combining with grapefruit juice (CYP3A4 inhibition may alter metabolism).

At pharmaceutical-grade purity and 4–30 mg/day dosing, methylene blue has a well-established safety profile based on decades of pharmaceutical use. The primary concerns are: drug interactions (particularly serotonergic drugs), G6PD deficiency (contraindication), and dose-dependent side effects above 30 mg/day.

Common (at any dose): blue-green urine and stool (normal excretion sign). Dose-dependent (>30mg): nausea, headache, dizziness, blue skin tinge. Serious (drug interaction): serotonin syndrome if combined with SSRIs/MAOIs. Rare: hemolytic anemia in G6PD-deficient individuals.

No. Methylene blue is a weak MAO inhibitor. Combining it with SSRIs, SNRIs, tricyclics, or other serotonergic medications risks serotonin syndrome, a potentially life-threatening condition. This interaction is documented and serious. Do not use methylene blue if you take any antidepressant without physician guidance.

Contraindications: G6PD deficiency (risk of hemolytic anemia), use of serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol), pregnancy and breastfeeding (insufficient safety data), and kidney disease (consult physician). Always review your medication list with a healthcare provider.

Yes, and this is expected and normal. The compound is a blue dye that is excreted in urine and stool, turning them blue-green. This is simply evidence of excretion and stops within 24 hours of discontinuing use. It is not a sign of harm.

CoQ10 and ubiquinol support the electron transport chain at Complex II-III. Methylene blue works differently — it can bypass dysfunctional Complex I and III, acting as a redox shuttle. The two are mechanistically complementary. Unlike CoQ10, methylene blue also crosses the blood-brain barrier making it relevant for cognitive applications.

NMN and NR boost NAD+ levels (a different mitochondrial coenzyme pathway). Methylene blue acts directly in the electron transport chain independent of NAD+ levels. They work on different nodes of mitochondrial function and can theoretically complement each other.

No. Methylene Blue Ultra uses capsule format. The capsule dissolves in the stomach, not the mouth. There is zero contact with oral tissues. This contrasts with sublingual troches (like Troscriptions Just Blue), which stain the mouth, tongue, and teeth blue for 2–6 hours.

No. Both deliver pharmaceutical-grade methylene blue, but the delivery format differs entirely. Troscriptions is a sublingual troche that dissolves under the tongue — causing significant oral staining. Methylene Blue Ultra is a capsule — zero staining, similar ~72% systemic bioavailability, easier to dose precisely.

Three things: (1) Pharmaceutical-grade USP purity at 99.9% — not all supplement-grade MB meets this standard. (2) Capsule format — zero staining, which competitors using liquid or sublingual formats cannot match. (3) Biomarker-integrated protocol — the only MB brand built around measurable biological outcomes via epigenetic age testing (TruDiagnostic partnership).

Methylene Blue Ultra launches Q3 2026. The founding member waitlist is open now at methyleneblueultra.com. Waitlist members receive priority access and founding member pricing.

Founding member pricing: $50–80/unit (final pricing TBD at launch). Waitlist members receive locked-in founding member rates.

USP pharmaceutical-grade, 99.9% purity. Every batch is independently third-party tested for purity, heavy metals, and contaminants.

TruDiagnostic provides epigenetic age testing via DNA methylation analysis. The MB Ultra protocol integrates this: (1) Baseline test before starting MB, (2) 90-day MB protocol at evidence-based dosing, (3) Retest to measure biological age delta. This is the only methylene blue brand that lets you measure whether the supplement moved your epigenetic clock.

Methylene blue has FDA recognition as a pharmaceutical antidote for methemoglobinemia (Provayblue®). As a dietary supplement, it operates under DSHEA framework with structure-function claims. MB Ultra uses the same pharmaceutical-grade purity standard as FDA pharmaceutical applications but is marketed as a dietary supplement, not a drug.